IP Library Granted Patent US 7,399,593
Granted Patent B1
US 7,399,593 · App. 09/868,533 · Granted Jul 15, 2008

Member of the TNF ligand family

Assignee: SmithKline Beecham Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,399,593
App. No.
09/868,533
Granted
Jul 15, 2008
Kind
B1
Abstract

The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of FIG. ( 1 ) or ii) a variant of the polypeptide of i).

Claims (7)

1. A method of screening for a compound that decreases the number of bound B cells by decreasing binding between a polypeptide comprising the amino acid sequence of SEQ ID NO:1 and the polypeptide's receptor expressed on B cells, the method comprising contacting said polypeptide and said B cell receptor in the presence of a test compound, where a decrease in binding of the polypeptide to the receptor, compared to that which would occur in the absence of said test compound, indicates said test compound decreases the binding of the polypeptide and the receptor, thereby decreasing the number of bound B cells.

2. The method according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

3. The method according to claim 1 , wherein the polypeptide is a trimer.

4. The method according to claim 1 , wherein the polypeptide is a homotrimer.

5. The method according to claim 2 , wherein the polypeptide is a trimer.

6. The method according to claim 2 , wherein the polypeptide is a homotrimer.

7. A method of screening for a compound that decreases the activation of NF-κB cells by decreasing binding between a polypeptide comprising the amino acid sequence of SEQ ID NO:1 and the polypeptide's receptor expressed on B cells, the method comprising contacting said polypeptide and said B cell receptor in the presence of a test compound, where a decrease in binding of the polypeptide to the receptor, compared to that which would occur in the absence of said test compound, indicates said test compound decreases the binding of the polypeptide and the receptor, thereby decreasing the activation of NF-κB cells.

Assignments (3)
CHANGE OF NAME Recorded Dec 17, 2009
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023660/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2009
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXO GROUP LIMITED
Reel/Frame 023409/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2007
From: FARROW, STUART NEVILLE; KAPTEIN, ALLARD; KITSON, JEREMY DAVID ALISTAIR; WINDER, ALISON JANET
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 020133/0761 →
Priority Claims (1)
GB 9828628.9 · Dec 23, 1998 · national